Skip to content
  • About us
    • Our DNA
    • Board members
    • Our leadership
    • Partners
  • Pipeline
    • VTX-801 – Wilson’s disease
    • > VTX-801 in Wilson disease – GATEWAY – Phase 1/2 Clinical Trial
    • VTX-802 & VTX-803 – PFIC
    • VTX-804 – Citrullinemia Type 1
    • VTX–806 – Cerebrotendinous Xanthomatosis
  • Investors
  • News
  • Events
  • Patients & Families
    • Patient’s Stories
    • Patient advocacy
    • Patient & Families ressources
    • Compassionate Use and Expanded Access
  • Work at Vivet
Menu
  • About us
    • Our DNA
    • Board members
    • Our leadership
    • Partners
  • Pipeline
    • VTX-801 – Wilson’s disease
    • > VTX-801 in Wilson disease – GATEWAY – Phase 1/2 Clinical Trial
    • VTX-802 & VTX-803 – PFIC
    • VTX-804 – Citrullinemia Type 1
    • VTX–806 – Cerebrotendinous Xanthomatosis
  • Investors
  • News
  • Events
  • Patients & Families
    • Patient’s Stories
    • Patient advocacy
    • Patient & Families ressources
    • Compassionate Use and Expanded Access
  • Work at Vivet

Author: admin_viv3t

Vivet presenting during the 2019 Bioprocessing Summit Europe in Lisbon

Vivet Therapeutics’ CEO, Jean-Philippe Combal

Vivet attending DIA Europe 2019 in Vienna on February 5-7

Anne Douar, Chief Development Officer of Vivet Therapeutics

VIVET WILL BE AT THE 37TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Jean-Philippe Combal, Vivet Therapeutics’ CEO

Vivet presenting at 2018 Evercore ISI HEALTHCONx in Boston

Vivet Therapeutics CEO, Jean-Philippe Combal

VIVET ATTENDING JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE

Jean-Philippe Combal, Vivet Therapeutics’ CEO, and Thomas Daniel, BD Director, will be hosting 1×1 meetings during Jefferies 2018 London Healthcare Conference on…

VIVET PRESENTING DURING 2018 GENE THERAPY FOR RARE DISORDERS EUROPE CONFERENCE IN LONDON

Anne Douar, Chief Development Officer of Vivet Therapeutics

VIVET THERAPEUTICS ATTENDING 2018 ESGCT 26TH ANNUAL CONGRESS IN LAUSANNE

Vivet Therapeutics will be at the upcoming European Society of Gene And Cell Therapy (ESGCT) 26th annual congress in Lausanne…

Vivet Presenting at 2018 Chardan Gene Therapy conference in New York

Vivet Therapeutics CEO, Jean-Philippe Combal, will be presenting and hosting 1×1 meetings during Chardan Gene Therapy conference in New York on October…

Vivet attending FierceBiotech 3rd Drug Development Forum in Boston

Vivet Therapeutics’ CEO, Jean-Philippe Combal

VIVET ANNOUNCES PRESENTATIONS ON ITS LEAD PRODUCT VTX-801 AT THE 2018 COPPER MEETING

Vivet Therapeutics announces different presentations

← Previous
Next →
Twitter Linkedin
About us
  • Our DNA
  • Board members
  • Our leadership
  • Partners
  • Our DNA
  • Board members
  • Our leadership
  • Partners
Pipeline
  • VTX-801 – Wilson’s disease
  • > VTX-801 in Wilson disease – GATEWAY
  • VTX-802 & VTX-803 – PFIC
  • VTX-804 – Citrullinemia Type 1
  • VTX – 806 – Cerebrotendinous Xanthomatosis
  • VTX-801 – Wilson’s disease
  • > VTX-801 in Wilson disease – GATEWAY
  • VTX-802 & VTX-803 – PFIC
  • VTX-804 – Citrullinemia Type 1
  • VTX – 806 – Cerebrotendinous Xanthomatosis
Patients & Families
  • Patient stories
  • Patient advocacy
  • Patient & Families ressources
  • Compassionate Use and Expanded Access
  • Patient stories
  • Patient advocacy
  • Patient & Families ressources
  • Compassionate Use and Expanded Access
  • News
  • Events
  • Investors
  • Work at Vivet
  • Contact
  • News
  • Events
  • Investors
  • Work at Vivet
  • Contact

Vivet Therapeutics Cookie Policy